palmitoylethanolamide + equisetum arvense

palmitoylethanolamide + equisetum arvense is a combination product containing **palmitoylethanolamide (PEA)**, a fatty acid amide known for its analgesic and anti-inflammatory properties, and **Equisetum arvense** (horsetail) extract, which possesses antioxidant and absorption-promoting effects[4][5]. The combination is primarily developed as a **nutraceutical approach** for the treatment and prevention of neuropathic and mixed pain, leveraging enhanced bioavailability, neuroprotective, anti-inflammatory, and analgesic action. Mechanistic data show this combination acts by modulation of the endocannabinoid system (increasing endocannabinoid levels, reducing FAAH and NAAA activity, upregulating CB2 receptor expression), enhancing PPARα activity, reducing pro-inflammatory cytokines (TNFα, IL-1β), suppressing oxidative stress, and promoting neurogenesis, myelin synthesis, and Schwann cell recovery, along with modulation of GABAergic and neurotrophic factors[3][4][5]. Preclinical studies demonstrate the combination crosses both the intestinal barrier and the blood-brain barrier, with a favorable safety profile and improved therapeutic efficacy compared to single agents[1][2][3][5]. The combination is marketed as a nutraceutical and is subject to pharmaceutical patent applications[5].

Brand names

EquiPEA

Other names

palmitoylethanolamide + equisetumEquisetum-PEAPEA + Equisetum arvense